The second shipment of medicines derived from Egyptian plasma arrives

The second shipment of medicines derived from Egyptian plasma arrived from Spain. The shipment included the immunoglobulin medicine, which treats primary and secondary immunodeficiency diseases, and the Factor 8 medicine for self-bleeding disorders (hemophilia), in addition to the human albumin medicine, which is used in emergencies, burns, liver and kidney diseases, and many other cases. Other pathological conditions.

This comes as a continuation of the efforts of the Armed Forces to support the medical system in accordance with the latest scientific knowledge in the field of health care and the pursuit of achieving self-sufficiency in plasma-derived medicines, and within the framework of close cooperation between the “Grifols Egypt” company, affiliated with the National Service Projects Agency for the Armed Forces, and “Griffols Egypt” company, which is affiliated with the National Service Projects Authority for the Armed Forces and the company “ Grifols of Spain, a leader in the field of plasma derivatives.

Increasing quantities of Egyptian plasma are currently being sent, which are being collected at the plasma donation centers affiliated with Grifols Egypt, which number 9 centers out of a total of 20 centers nationwide, all of which are subject to the highest international standards of quality and safety.

Meanwhile, Major General Doctor Magdy Amin Mubarak, Chairman of the Board of Directors of “Grifols Egypt”, confirmed that shipments of medicines derived from Egyptian plasma are expected to arrive successively, which confirms the keenness on the continuous supply of these essential medicines that help strengthen the health care system in Egypt, noting that the process Sending plasma abroad and returning it as final pharmaceutical products to Egypt is done temporarily until the completion of construction and operation of the factory being built in the Medical City in the New Administrative Capital, which is the first of its kind in the Middle East and Africa.